Joanne Goodman
Joanne Goodman has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Michaela Golob
Nuvisan GmbH
2 shared publicationsBarry W A van der Strate
PRA Health Sciences, Assen, The Netherlands
1 shared publicationBirgit Jaitner
Novartis Pharma AG, Basel, Switzerland
1 shared publication- Chad Briscoe
Global Bioanalytical Services, Celerion, Lincoln, NE 68502, USA
1 shared publication Daniel Thwaites
Labcorp Drug Development
1 shared publicationFrazer Lambert
Charles River Laboratories
1 shared publication
Latest Publications
- 6 November 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (1) , 1-5
Cross-validation of pharmacokinetic assays post-ICH M10 is not a pass/fail criterion
The ICH M10 guideline establishes global standards for bioanalytical method validation for pharmacokinetic assays, focusing on data reliability and accuracy across studies. A significant component is cross-validation, which should be performed to ensure data comparability when multiple methods or laboratories are involved in a single study or across studies where comparison will be performed. However, ICH M10 does not specify acceptance criteria for cross-validation, creating challenges for the industry because traditionally many laboratories have always utilized acceptance criteria to "pass" or "fail" the study. This editorial discusses how bioanalytical labs should conduct cross-validation for PK assays post-ICH M10, highlighting the role of statistical methods and the need for close collaboration with clinical pharmacology and biostatistics departments. Proper implementation and strategic focus on relevant studies are essential for effective cross-validation.
- 6 November 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 17 (1) , 1-5
Cross-validation of pharmacokinetic assays post-ICH M10 is not a pass/fail criterion
The ICH M10 guideline establishes global standards for bioanalytical method validation for pharmacokinetic assays, focusing on data reliability and accuracy across studies. A significant component is cross-validation, which should be performed to ensure data comparability when multiple methods or laboratories are involved in a single study or across studies where comparison will be performed. However, ICH M10 does not specify acceptance criteria for cross-validation, creating challenges for the industry because traditionally many laboratories have always utilized acceptance criteria to "pass" or "fail" the study. This editorial discusses how bioanalytical labs should conduct cross-validation for PK assays post-ICH M10, highlighting the role of statistical methods and the need for close collaboration with clinical pharmacology and biostatistics departments. Proper implementation and strategic focus on relevant studies are essential for effective cross-validation.
- Open Access
- 5 August 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (16) , 835-842
A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays
The European Bioanalysis Forum, alongside key industry stakeholders, has been driving the discussions around the implementation of context-of use for biomarker assays to ensure that these assays are validated appropriately depending on their purpose. Insights into understanding why the implementation of context-of-use in assay strategies has also shown that the key stakeholder, or requester for the biomarker data, is responsible for providing the context-of-use statement for all biomarker assay requests. Experts from across the industry haves repeatedly sought a cross-industry recommended format in which the context-of-use statement could be provided. In this manuscript, the European Bioanalysis Forum suggests a format for this.
- 5 August 2024
- Published by Taylor & Francis in Bioanalysis
- Vol. 16 (16) , 835-842
Open AccessA European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays
The European Bioanalysis Forum, alongside key industry stakeholders, has been driving the discussions around the implementation of context-of use for biomarker assays to ensure that these assays are validated appropriately depending on their purpose. Insights into understanding why the implementation of context-of-use in assay strategies has also shown that the key stakeholder, or requester for the biomarker data, is responsible for providing the context-of-use statement for all biomarker assay requests. Experts from across the industry haves repeatedly sought a cross-industry recommended format in which the context-of-use statement could be provided. In this manuscript, the European Bioanalysis Forum suggests a format for this.
- Open Access
- 18 September 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (19) , 1557-1565
EBF Recommendation on Practical Management of Critical Reagents for PK Ligand-Binding Assays
Critical reagents play a crucial role in ligand binding assays; the robustness and reliability of an assay is defined by the quality and long-term availability of these reagents. However, neither regulatory guidelines nor relevant scientific papers provide clear directions for set-up, life cycle management and, more importantly, the acceptance criteria required for the testing of the critical reagents for pharmacokinetic, biomarker and immunogenicity assays. The ambiguity from current guidelines can be a challenge for the bioanalytical community. Members of the European Bioanalysis Forum community undertook a more pragmatic approach on how to assess the impact of critical reagents. In this paper, a review and corresponding gap analysis of the current guidelines and relevant papers will be provided as well as decision trees proposed for lot-to-lot changes of critical reagents for pharmacokinetic assays.
- 18 September 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (19) , 1557-1565
Open AccessEBF Recommendation on Practical Management of Critical Reagents for PK Ligand-Binding Assays
Critical reagents play a crucial role in ligand binding assays; the robustness and reliability of an assay is defined by the quality and long-term availability of these reagents. However, neither regulatory guidelines nor relevant scientific papers provide clear directions for set-up, life cycle management and, more importantly, the acceptance criteria required for the testing of the critical reagents for pharmacokinetic, biomarker and immunogenicity assays. The ambiguity from current guidelines can be a challenge for the bioanalytical community. Members of the European Bioanalysis Forum community undertook a more pragmatic approach on how to assess the impact of critical reagents. In this paper, a review and corresponding gap analysis of the current guidelines and relevant papers will be provided as well as decision trees proposed for lot-to-lot changes of critical reagents for pharmacokinetic assays.